SEC Form 4 · accession 0001104659-18-044054
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy B Lowinger
Officer — Chief Scientific Officer
Period of report
Jul 3, 2018
Accepted (ET)
Jul 5, 2018 · 6:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 3, 2018 | M | 10,000 | $1.40 | A | 15,991 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $1.40 | Jul 3, 2018 | M | 10,000 | D | — | Oct 1, 2022 | Common Stock | 10,000 | 93,333 | D |
Explanation of responses
- F1The option vested 25% on August 1, 2013 and in equal quarterly installments thereafter.